{"disease":{"id":"cancer-surgery","name":"cancer surgery"},"drugs":{"marketed":[{"drug_id":"levoxyl","indication_name":"TSH suppression in thyrotropin-dependent well-differentiated thyroid cancer - adjunct to surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levoxyl","generic_name":"Levothyroxine Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Thyroid receptor proteins attached to DNA","drug_class":"Thyroid hormone replacement","quality_score":10,"revenue":null,"mechanism":"Levothyroxine binds thyroid receptors in cell nuclei to activate gene transcription and protein synthesis."},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, and/or prior surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, and/or prior hormone therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, and/or prior targeted therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, and/or prior immunotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, and/or prior chemotherapy with a taxane","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, and/or prior chemotherapy with a platinum agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, and/or prior chemotherapy with a microtubule inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, and/or prior chemotherapy with a PARP inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, and/or prior chemotherapy with a CDK4/6 inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, and/or prior chemotherapy with a mTOR inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, and/or prior chemotherapy with a HER2-targeted therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, and/or prior chemotherapy with a PIK3CA-targeted therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, and/or prior chemotherapy with a hormone receptor antagonist","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, and/or prior chemotherapy with a hormone receptor agonist","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, and/or prior chemotherapy with a selective estrogen receptor degrader","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, and/or prior chemotherapy with a selective estrogen receptor modulator","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, prior chemotherapy with a selective estrogen receptor modulator, and/or prior chemotherapy with a cyclin-dependent kinase 4/6 inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, prior chemotherapy with a selective estrogen receptor modulator, prior chemotherapy with a cyclin-dependent kinase 4/6 inhibitor, and/or prior chemotherapy with a CDK4/6 inhibitor and/or a PIK3CA inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":19,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06959849","title":"Robot-assisted Surgery for Colorectal Cancer Resection: A Population-based Analysis of Prevalence, Trends and Outcomes","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":128000,"lead_sponsor_name":"Medizinische Hochschule Brandenburg Theodor Fontane","has_results":false},{"nct_id":"NCT07059104","title":"Implant-based Breast Reconstruction in Post-bariatric Women - a Registry-based National Study","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT03567538","title":"National Register Studies in Thoracic Surgery","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT05086601","title":"A Cohort of Molecular Characteristics and Prognosis of Colorectal Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05452538","title":"AutoTransfusion Versus TRAnsfusion in Cancer Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":5808,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT06330038","title":"Anesthesia and Non-small Cell Lung Cancer Recurrence","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":5384,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT06888388","title":"Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":4700,"lead_sponsor_name":"Sir Mortimer B. Davis - Jewish General Hospital","has_results":false},{"nct_id":"NCT06684223","title":"Analysis of Surgical and Oncologic Outcomes After Complete Mesocolic Excision or Non-complete Mesocolic Excision for Right-Sided Colon Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":3787,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT06865586","title":"A Comparative Study of Tumor Specific Mesocolic Excision and Complete Mesocolic Excision for Right Sided Colon Cancer : Asian Multicenter Retrospective Study","phase":"","overall_status":"COMPLETED","enrollment_count":3326,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT03461341","title":"European iNvestigation of SUrveillance After Resection for Esophageal Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"St. James's Hospital, Ireland","has_results":false},{"nct_id":"NCT04844671","title":"Patients' Expectations About Effects of Robotic Surgery for Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT05851534","title":"Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas","phase":"NA","overall_status":"RECRUITING","enrollment_count":2575,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT04799509","title":"Assessment of the 90-day Mortality Risk Score After VATS Lobectomy","phase":"","overall_status":"COMPLETED","enrollment_count":2209,"lead_sponsor_name":"Università degli Studi dell'Insubria","has_results":false},{"nct_id":"NCT04326088","title":"Postoperative Complication After Free Flap Reconstruction for Head and Neck Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":2004,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT04821843","title":"Neoadjuvant Treatment Modalities in Esophageal Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05650125","title":"A Platform Study for solId orgaN CancERs","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Liverpool","has_results":false},{"nct_id":"NCT07512232","title":"Intraoperative Rectal Lavage to Prevent Local Recurrence After Laparoscopic Mid-to-Low Rectal Cancer Resection: A Multicenter Randomized Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":1598,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04397575","title":"The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1523,"lead_sponsor_name":"Federation Francophone de Cancerologie Digestive","has_results":false},{"nct_id":"NCT06761196","title":"Quality of Life After Breast Cancer Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Centre Hospitalier de Colmar","has_results":false},{"nct_id":"NCT04596865","title":"Recurrence After Whipple's (RAW) Study","phase":"","overall_status":"COMPLETED","enrollment_count":1484,"lead_sponsor_name":"University Hospital Plymouth NHS Trust","has_results":false},{"nct_id":"NCT03982641","title":"Emilia-Romagna Surgical Colorectal Cancer Audit- ESCA","phase":"","overall_status":"UNKNOWN","enrollment_count":1400,"lead_sponsor_name":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","has_results":false},{"nct_id":"NCT06764888","title":"ERAS in Elderly Colorectal Cancer Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":1392,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT06869629","title":"Omission of Axillary Lymph Node Dissection in Case of Tumor Spread to Lymph Nodes in the Armpit in Breast Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1380,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT07185568","title":"IntraOperative UltraSound Guided vs Wire Guided vs Magnetic Seed Guided Breast-Conserving Surgery for Non-palpable Tumors","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1302,"lead_sponsor_name":"Istituto Oncologico Veneto IRCCS","has_results":false},{"nct_id":"NCT04893876","title":"The OPERa Study: Evaluating QoL After Rectal Cancer Surgery","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Jewish General Hospital","has_results":false},{"nct_id":"NCT06376227","title":"Robotic-Assisted or Laparoscopic Radical Resection for Rectal Cancer With or Without Left Colic Artery Preservation","phase":"","overall_status":"COMPLETED","enrollment_count":1164,"lead_sponsor_name":"Northern Jiangsu People's Hospital","has_results":false},{"nct_id":"NCT04579861","title":"GO SOAR1: Post-Operative Morbidity and Mortality Following Gynaecological Oncology Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":1100,"lead_sponsor_name":"Faiza Gaba","has_results":false},{"nct_id":"NCT02642471","title":"Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-stage Cervical Cancer (PHENIX/CSEM 010)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1080,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04593615","title":"Indocyanine Green Tracer Using in Laparoscopic Radical Gastrectomy for Locally Advanced Gastric Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1070,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT04286984","title":"Implementation of a Patient Blood Management Program in Gastric Cancer Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":1063,"lead_sponsor_name":"Hospital Universitari de Bellvitge","has_results":false},{"nct_id":"NCT04488549","title":"Delayed Colorectal Cancer Care During Coronavirus Disease (COVID-19) Pandemic (DECOR-19)","phase":"","overall_status":"COMPLETED","enrollment_count":1051,"lead_sponsor_name":"Treviso Regional Hospital","has_results":false},{"nct_id":"NCT06728527","title":"PARTial BREast RECONstruction With Chest Wall Perforator Flap","phase":"","overall_status":"RECRUITING","enrollment_count":1001,"lead_sponsor_name":"Cambridge University Hospitals NHS Foundation Trust","has_results":false},{"nct_id":"NCT04384926","title":"Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"University of Birmingham","has_results":false},{"nct_id":"NCT06425874","title":"The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT02056886","title":"Medico-economic Study of Three Strategies of Sentinel Lymph Node Analysis in Operable Breast Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":858,"lead_sponsor_name":"Institut Cancerologie de l'Ouest","has_results":false},{"nct_id":"NCT04663191","title":"Intraoperative Conversion During Video-assisted Thoracoscopy Resection for Lung Cancer Does Not Alter Survival","phase":"","overall_status":"COMPLETED","enrollment_count":843,"lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","has_results":false},{"nct_id":"NCT06180239","title":"Segmentectomy vs Lobectomy","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06906601","title":"Preoperative Magnetic Tracking in Breast Surgery in France: French Medical-economic Study.","phase":"","overall_status":"RECRUITING","enrollment_count":772,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT05942209","title":"ECO-LEAK Technique: Early Detection of Colorectal Anastomotic Leakage by Transvaginal Ultrasound","phase":"","overall_status":"UNKNOWN","enrollment_count":766,"lead_sponsor_name":"Instituto de Investigacion Sanitaria La Fe","has_results":false},{"nct_id":"NCT06945718","title":"Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30)","phase":"","overall_status":"RECRUITING","enrollment_count":760,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT05891301","title":"Construction and Validation of Risk Prediction Model for Gastrointestinal Dysfunction of Patient With Colorectal Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":737,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05434520","title":"Relieving the Bile Ducts Prior to Pancreatoduodenectomy","phase":"","overall_status":"COMPLETED","enrollment_count":722,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT06161207","title":"3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":702,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT06361862","title":"Does Continuous Vital Sign Monitoring Increase Investigations and Interventions in Complication-free Patients?","phase":"NA","overall_status":"COMPLETED","enrollment_count":700,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT04108117","title":"Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction","phase":"","overall_status":"COMPLETED","enrollment_count":659,"lead_sponsor_name":"Severance Hospital","has_results":false},{"nct_id":"NCT04853784","title":"Prospective Registration Study of Totally Laparoscopy Versus Laparoscopy Assisted Colon Cancer Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":650,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT04843189","title":"Prospective Registration Study of Robtic Laparoscopy Versus Laparoscopy Assisted Colon Cancer Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":648,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT06405308","title":"Robotic Natural Orifice Specimen Extraction Surgery Versus Robotic Transabdominal Specimen Extraction Surgery for Early-Stage Rectal Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":636,"lead_sponsor_name":"Taiyuan Li","has_results":false},{"nct_id":"NCT04416854","title":"The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":627,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06421974","title":"Effectiveness of Robotic Surgery for Right Colon Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":610,"lead_sponsor_name":"Sir Run Run Shaw Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}